Pyxis Oncology, Inc.

NASDAQ:PYXS

Biotechnology

Healthcare
$1.41 +5.53%

+$0.11 today

Market cap
$168.65M
Beta
1.43
P/E (TTM)
-1.6
EPS (TTM)
-$1.29
52W Low $0.97High $5.55

Volume 0.75M

Average 0.50M

PYXS Short-term Investments

Marketable securities and deposits the company expects to convert to cash within a year.

Pyxis Oncology, Inc.NASDAQ: PYXS

Short-term Investments · Q1 FY2026 · quarter ended Mar 2026

Short-term investments falls 62.0% from a year ago

Short-term investments stood at $35.25M at the end of Q1 FY2026, down 62.0% from a year earlier and down 31.5% from the prior quarter.

Context

  • Short-term investments amounted to 54.8% of total assets at the end of Q1 FY2026, down 13.4 pp from a year earlier.
  • Short-term investments increased in 1 of the last 3 fiscal years.

What to watch

Whether short-term investments keeps falling in the next quarterly balance sheet after a -62.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$35.25M-31.5% QoQ
Last fiscal yearDec 2025
$51.44M-52.1% YoY
Year agoMar 2025
$92.67M-62.0% since
Short-term Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-62.0%——
1 year-52.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Short-term Investments history

USD · from the balance sheet

Latest · FY2025
51.44M USD
Year-over-year change
-52.1%

Short-term Investments vs competitors

How PYXS compares with its peers on the latest reported figures

  • PYXS's Mar 2026 short-term investments of $35.25M is the 7th highest of the 10 companies compared; the peer median is $98.17M.
  • Its year-over-year change of -62.0% is the 6th highest of 7, against a peer median of -40.4%.
  • Short-term investments amounts to 54.8% of total assets for PYXS, versus a peer median of 40.9%.
PYXS Competitors Peer median
Short-term Investments for PYXS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
AVIRAtea Pharmaceuticals, Inc.Mar 2026$176.69M -42.3%—66.2%
ENTAEnanta Pharmaceuticals, Inc.Mar 2026$128.85M -3.2%-8.6%40.9%
IMRXImmuneering CorporationMar 2026$109.37M —+10.3%0.1%
CRBUCaribou Biosciences, Inc.Mar 2026$105.57M -41.0%-12.5%70.9%
VYGRVoyager Therapeutics, Inc.Mar 2026$98.17M -39.1%+87.5%44.8%
FHTXFoghorn Therapeutics Inc.Mar 2026$95.97M -39.9%-35.7%43.2%
PYXSPyxis Oncology, Inc.Mar 2026$35.25M -62.0%—54.8%
HUMAHumacyte, Inc.Mar 2026$0 ——0.0%
ZURAZura Bio LimitedMar 2026$0 ——0.0%
TNYATenaya Therapeutics, Inc.Mar 2026$0 -100.0%—0.0%
Peer median (excluding PYXS) $98.17M-40.4%-8.6%40.9%

Competitors are the stored peer set for PYXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents274.74M179.29M9.66M19.47M15.42M
Short-term Investments00109.63M107.46M51.44M
Net Receivables0598K21K0700K
Inventory00000
Other Current Assets1.56M5.41M4.27M4.75M4.55M
Total Current Assets278.67M186.61M124.6M132.44M72.11M
Property, Plant & Equipment (Net)1.24M24.77M24.81M22.14M19.42M
Goodwill00000
Intangible Assets0024.31M2.6M0
Long-term Investments00000
Tax Assets00000
Other Non-current Assets109K0000
Total Non-current Assets1.35M24.77M49.12M24.74M19.42M
Total Assets280.02M211.38M173.73M157.18M91.52M
Account Payables11.95M7.1M3.9M4.86M10.89M
Short-term Debt00000
Tax Payables00000
Deferred Revenue007.66M00
Other Current Liabilities3.23M5.33M5.58M4.63M3.75M
Total Current Liabilities18.71M31.63M25.76M17.68M21.13M
Long-term Debt00000
Deferred Tax Liabilities002.16M00
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities018.92M22.26M18.75M16.98M
Total Liabilities18.71M50.56M48.02M36.43M38.11M
Common Stock32K34K45K60K63K
Retained Earnings(91.72M)(212.44M)(286.23M)(363.56M)(443.18M)
Accumulated OCI0063K170K53K
Other Stockholders Equity00000
Minority Interest00000
Total Equity261.31M160.82M125.7M120.75M53.41M
Total Debt165K18.92M21.33M20.2M18.67M
Net Debt(274.57M)(160.37M)11.67M727K3.25M

Pyxis Oncology, Inc.

NASDAQ:PYXS

Intrinsic Alpha fair value

Locked

Current Price

$1.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.